May 05, 2025 Deadline: Contact Levi & Korsinsky LLP to Join Class Action Suit Against MRVI
TipRanks (Wed, 5-Mar 3:20 PM ET)
Globe Newswire (Wed, 5-Mar 1:25 PM ET)
Business Wire (Wed, 5-Mar 11:47 AM ET)
Globe Newswire (Wed, 5-Mar 11:29 AM ET)
Globe Newswire (Wed, 5-Mar 11:22 AM ET)
Hold Rating on Maravai Lifesciences Due to Filing Delays and Financial Reporting Concerns
TipRanks (Wed, 5-Mar 10:45 AM ET)
Globe Newswire (Wed, 5-Mar 10:32 AM ET)
Craig-Hallum Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
TipRanks (Wed, 5-Mar 9:26 AM ET)
Business Wire (Wed, 5-Mar 9:00 AM ET)
Stifel Nicolaus Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)
TipRanks (Wed, 5-Mar 8:19 AM ET)
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Maravai Lifesciences Holdings - Class A trades on the NASDAQ stock market under the symbol MRVI.
As of March 5, 2025, MRVI stock price declined to $2.81 with 6,959,026 million shares trading.
MRVI has a beta of 0.87, meaning it tends to be less sensitive to market movements. MRVI has a correlation of 0.02 to the broad based SPY ETF.
MRVI has a market cap of $398.58 million. This is considered a Small Cap stock.
Last quarter Maravai Lifesciences Holdings - Class A reported $65 million in Revenue and -$.02 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.01.
In the last 3 years, MRVI traded as high as $41.82 and as low as $2.73.
The top ETF exchange traded funds that MRVI belongs to (by Net Assets): VTI, VB, VXF, VBK, IWM.
MRVI has underperformed the market in the last year with a price return of -63.1% while the SPY ETF gained +15.2%. MRVI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -48.1% and -31.5%, respectively, while the SPY returned -3.7% and -4.6%, respectively.
MRVI support price is $2.70 and resistance is $2.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRVI shares will trade within this expected range on the day.